Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 9127 results

  1. Ruxolitinib cream for treating moderate atopic dermatitis after topical corticosteroids and calcineurin inhibitors ID6602

    In development Reference number: GID-TA11809 Expected publication date:  03 June 2027

    Technology appraisal guidance
    In development

  2. Excimer laser trabeculotomy for open angle glaucoma

    In development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    In development

  3. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date:  24 June 2027

    HealthTech guidance
    In development

  4. Severe mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  5. Insulin efsitora alfa for treating type 2 diabetes [ID6499]

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  6. Imlunestrant for adjuvant treatment of ER-positive, HER2-negative early breast cancer with increased risk of recurrence

    Awaiting development Reference number: GID-TA12459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Novel risk profiling technologies to guide adjuvant chemotherapy decisions in early breast cancer

    Awaiting development Reference number: GID-HTG10904 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Ianalumab for treating active Sjogren's disease ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628

    In development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]

    Awaiting development Reference number: GID-TA11849 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]

    In development Reference number: GID-HST10069 Expected publication date:  11 April 2027

    Highly specialised technologies guidance
    In development

  14. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-HTG10881 Expected publication date:  11 February 2027

    HealthTech guidance
    In development